Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Founder Elisabet de los Pinos has stepped down as CEO and President, succeeded by Natalie Holles effective April 30, 2026. Holles brings 25 years of experience, including previous leadership roles at Third Harmonic Bio and Audentes Therapeutics, signaling a shift toward commercialization capabilities. The Phase 3 CoMpass trial for bel-sar is nearing completion with 86 patients enrolled and over 25 patients scheduled for screening. Management reiterated guidance for enrollment completion by mid-2026 and topline data in the second half of 2027.
Key figures
- Drug Name
- belzupacap sarotalocan (bel-sar)
- Phase Of Trial
- Phase 3
- Patients enrolled
- 86
- Guidance topline data
- second half of 2027
- Patients screening scheduled
- >25
- Guidance enrollment completion
- mid-2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.